Genelux (NASDAQ:GNLX - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report released on Saturday, Wall Street Zen reports.
Several other equities analysts have also recently commented on GNLX. Lucid Cap Mkts upgraded shares of Genelux to a "strong-buy" rating in a research report on Wednesday, September 16th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Genelux in a research report on Thursday, October 15th. Finally, Benchmark reiterated a "speculative buy" rating on shares of Genelux in a research report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Genelux currently has an average rating of "Moderate Buy" and a consensus price target of $20.00.
Check Out Our Latest Stock Report on GNLX
Genelux Stock Down 4.8%
GNLX stock opened at $2.17 on Friday. The company has a market cap of $98.17 million, a PE ratio of -2.47 and a beta of 0.68. The business has a 50-day simple moving average of $2.28 and a 200 day simple moving average of $2.64. Genelux has a 52 week low of $1.77 and a 52 week high of $5.89.
Genelux (NASDAQ:GNLX - Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.03). On average, analysts anticipate that Genelux will post -0.85 EPS for the current fiscal year.
Insider Buying and Selling at Genelux
In related news, CEO Thomas Zindrick sold 34,463 shares of the firm's stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $2.67, for a total value of $92,016.21. Following the sale, the chief executive officer directly owned 1,226,427 shares of the company's stock, valued at $3,274,560.09. This trade represents a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Yong Yu sold 9,683 shares of the business's stock in a transaction on Monday, August 31st. The stock was sold at an average price of $2.75, for a total transaction of $26,628.25. Following the sale, the insider directly owned 258,688 shares in the company, valued at approximately $711,392. The trade was a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 47,903 shares of company stock valued at $126,320. 7.50% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Genelux
Hedge funds and other institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new stake in shares of Genelux during the second quarter valued at about $35,000. Strive Financial Group LLC grew its holdings in shares of Genelux by 728.7% during the second quarter. Strive Financial Group LLC now owns 41,437 shares of the company's stock worth $125,000 after purchasing an additional 36,437 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Genelux by 30.4% in the third quarter. Goldman Sachs Group Inc. now owns 59,727 shares of the company's stock valued at $151,000 after buying an additional 13,918 shares during the period. Trek Financial LLC acquired a new position in shares of Genelux during the third quarter valued at about $158,000. Finally, AMG National Trust Bank bought a new position in Genelux in the second quarter worth approximately $227,000. Institutional investors own 37.33% of the company's stock.
Genelux Company Profile
(
Get Free Report)
Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company's lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genelux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genelux wasn't on the list.
While Genelux currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.